EWA
IKT icon

EverSource Wealth Advisors’s Inhibikase Therapeutics IKT Stock Holding History

EverSource Wealth Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74K Buy
857
+644
+302% +$1.15K ﹤0.01% 3774
2026
Q1 		$357 Buy
213
+209
+5,225% +$371 ﹤0.01% 4115
2025
Q4 		$8 Buy
+4
New +$6 ﹤0.01% 4252

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EverSource Wealth Advisors's IKT Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Inhibikase Therapeutics (IKT) stake by 302% in Q2 2026, buying an estimated $1.15K and bringing the position to 857 shares worth $1.74K. The position accounts for ﹤0.01% of the portfolio, ranked #3774.

EverSource Wealth Advisors first reported a position in IKT in Q4 2025 and has held it in 3 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • EverSource Wealth Advisors held 857 shares of Inhibikase Therapeutics worth $1.74K as of Q2 2026.
  • EverSource Wealth Advisors bought 644 Inhibikase Therapeutics shares in Q2 2026, an estimated $1.15K.
  • Inhibikase Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3774 holding.
  • EverSource Wealth Advisors first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.